Is Ixazomib a chemotherapy drug or a targeted drug?

Ixazomib is a reversible inhibitor of the proteasome (proteasome inhibitor) and a targeted anti-cancer drug used to treat multiple myeloma (MM). It can be used in combination with lenalidomide and dexamethasone to increase its therapeutic effect.

In normal cells there is an enzyme complex (called the proteasome) that acts like a recycling center to break down any unwanted or damaged proteins into smaller parts, so the damaged or unwanted proteins do not accumulate within the cell. Ixazomib blocks or inhibits the work of an enzyme complex (proteasome), which means the accumulation of damaged and unwanted proteins within cells. Myeloma cancer cells are very sensitive to excess extra or damaged proteins within them, and when this happens, it causes the myeloma cancer cells to die. Ixazomib is an oral medication that is taken by mouth in capsule form, making it easier to take than intravenous medications.

The original drug of Ixazomib has been launched in China and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 US dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.